Scopus BioPharma Statistics
Share Statistics
Scopus BioPharma has 42.08M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 42.08M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.36% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 23.77K, so undefined% of the outstanding
shares have been sold short.
| Short Interest | 23.77K |
| Short % of Shares Out | n/a |
| Short % of Float | 0.07% |
| Short Ratio (days to cover) | 0.22 |
Valuation Ratios
The PE ratio is -0.18 and the forward
PE ratio is null.
Scopus BioPharma's PEG ratio is
0.
| PE Ratio | -0.18 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -0.31 |
| P/FCF Ratio | -0.25 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Scopus BioPharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05,
with a Debt / Equity ratio of 0.
| Current Ratio | 0.05 |
| Quick Ratio | 0.05 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-893,063.62 |
| Employee Count | 13 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -105.05K |
| Effective Tax Rate | 0.9% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is -2.01, so Scopus BioPharma's
price volatility has been lower than the market average.
| Beta | -2.01 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0 |
| Relative Strength Index (RSI) | 47.79 |
| Average Volume (20 Days) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.71M |
| Net Income | -11.61M |
| EBITDA | -11.71M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.55 |
Full Income StatementBalance Sheet
The company has 124.58K in cash and 0 in
debt, giving a net cash position of 124.58K.
| Cash & Cash Equivalents | 124.58K |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -53.06M |
| Total Assets | 497.55K |
| Working Capital | -10.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -8.13M
and capital expenditures -1.55K, giving a free cash flow of -8.13M.
| Operating Cash Flow | -8.13M |
| Capital Expenditures | -1.55K |
| Free Cash Flow | -8.13M |
| FCF Per Share | -0.39 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
